Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean di panthenol and hyaluronic acid?
Displaying drugs 2401 - 2425 of 15118 in total

Streptomycin

Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic...
Approved
Vet approved
Matched Description: … Medicine for their discovery of streptomycin and its antibacterial activity. ... [A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in ... Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and …
Matched Categories: … Alimentary Tract and Metabolism ... streptomycin and isoniazid …

BCG vaccine

BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
Approved
Investigational
Matched Description: … investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Pacritinib

Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. While some patients may remain asymptomatic, typical symptoms of MF...
Approved
Investigational
Matched Description: … [L40793] JAK2 signaling is important for hematopoiesis and proper immune functioning,[L40754] and while ... Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within ... may therefore include various cytopenias, infections, splenomegaly, and general systemic symptoms such …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Thiothixene

A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.
Approved

Levosimendan

Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
Approved
Investigational

Aducanumab

Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab.[A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a...
Approved
Investigational
Matched Description: … that targets extracellular amyloid-β plaques in the brain; similar to [gantenerumab], [bapineuzumab] and ... ] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and ... [A235668] Based on Mini-Mental State Examination and Clinical Dementia Rating (CDR), patients taking …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Gefapixant

It has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond...
Approved
Investigational
Matched Description: … and UCC, and received subsequent approval in the EU in September 2023 for the same indications. ... [L48601] A subset of these patients remain symptomatic despite thorough investigation and treatment, ... It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC …
Matched Categories: … Cough and Cold Preparations …

Thiabendazole

2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)
Approved
Vet approved
Matched Description: … It has CNS side effects and hepatototoxic potential. ... (From Smith and Reynard, Textbook of Pharmacology, 1992, p919) ... It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. …
Matched Categories: … Imidazole and Triazole Derivatives ... Antiparasitic Products, Insecticides and Repellents …

Ponesimod

Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than fingolimod. Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to...
Approved
Investigational
Matched Description: … sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Evinacumab

Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in...
Approved
Investigational
Matched Description: … [L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively ... provides a unique and synergistic therapeutic option in the treatment of HoFH. ... a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Phenacemide

Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
Approved
Matched Description: … This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures. …

Chromic nitrate

Approved

Chromous sulfate

Approved

DaxibotulinumtoxinA

DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.[A261075, L47860] DaxibotulinumtoxinA was...
Approved
Matched Description: … DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. …

Tositumomab

Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …

Pipotiazine

Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is...
Approved
Investigational
Matched Description: … for causing hypotension or potentiating the effects of CNS depressants and anesthetics. ... Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity ... Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation …

Crofelemer

Crofelemer, previously known as the investigational drug SP-303, is a novel proanthocyanidin purified from the bark latex of the Amazonian Croton tree Croton lechleri. It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral...
Approved
Matched Description: … It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious …
Matched Categories: … Alimentary Tract and Metabolism …

Tedizolid

Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the...
Approved
Investigational
Matched Description: … ) and is generally more effective and more tolerable than [linezolid]. ... such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and ... member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and …

Deutetrabenazine

Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated DB04844 . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity...
Approved
Investigational
Matched Description: … It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046]. ... This allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043]. ... It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. …
Matched Categories: … Tetrabenazine and isomer …

Leniolisib

Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of...
Approved
Investigational
Matched Description: … Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). ... in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Levobupivacaine

Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a...
Approved
Investigational
Matched Description: … intrathecal anaesthesia in adults; and infiltration analgesia in children. ... specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and ... predominantly associated with inappropriate administration methods that may cause systemic exposure and …

Trastuzumab emtansine

Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis....
Approved
Investigational
Matched Description: … First that trastuzumab emtansine and trastuzumab cannot be interchanged. ... anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. ... T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Ropeginterferon alfa-2b

Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia.[A242000, A242005] Interferon alfa-2b has been used for decades to treat PV but requires frequent dosing...
Approved
Investigational
Matched Description: … and clinical trials. ... platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term ... propensity for myelofibrosis and leukemia. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Plerixafor

Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.[A7117,L45678] It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune...
Approved
Investigational
Matched Description: … [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved ... Since CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment ... by the US Food and Drug Administration on December 15, 2008. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Riociguat

Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension)...
Approved
Matched Description: … Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other ... regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for …
Displaying drugs 2401 - 2425 of 15118 in total